These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 36229854)

  • 1. ARID1A deficiency reverses the response to anti-PD(L)1 therapy in EGFR-mutant lung adenocarcinoma by enhancing autophagy-inhibited type I interferon production.
    Sun D; Qian H; Wang J; Xie T; Teng F; Li J; Xing P
    Cell Commun Signal; 2022 Oct; 20(1):156. PubMed ID: 36229854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiomics analysis revealed the mechanisms related to the enhancement of proliferation, metastasis and EGFR-TKI resistance in EGFR-mutant LUAD with ARID1A deficiency.
    Sun D; Feng F; Teng F; Xie T; Wang J; Xing P; Qian H; Li J
    Cell Commun Signal; 2023 Mar; 21(1):48. PubMed ID: 36869329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma.
    Yang L; He YT; Dong S; Wei XW; Chen ZH; Zhang B; Chen WD; Yang XR; Wang F; Shang XM; Zhong WZ; Wu YL; Zhou Q
    J Immunother Cancer; 2022 Jan; 10(2):. PubMed ID: 35140113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 5. YAP1 as a Novel Negative Biomarker of Immune Checkpoint Inhibitors for EGFR-Mutant Non-Small-Cell Lung Cancer.
    Li LC; Chen XW; Fang L; Jian CL; Yu YX; Liao XY; Sun JG
    Can Respir J; 2023; 2023():4689004. PubMed ID: 37388902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Combined Use of Everolimus and Second-Generation Pan-EGRF Inhibitors in
    da Silva-Oliveira RJ; Gomes INF; da Silva LS; Lengert AVH; Laus AC; Melendez ME; Munari CC; Cury FP; Longato GB; Reis RM
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subunits of ARID1 serve as novel biomarkers for the sensitivity to immune checkpoint inhibitors and prognosis of advanced non-small cell lung cancer.
    Sun D; Tian L; Zhu Y; Wo Y; Liu Q; Liu S; Li H; Hou H
    Mol Med; 2020 Aug; 26(1):78. PubMed ID: 32791957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of ARID1A expression promotes lung adenocarcinoma metastasis and predicts a poor prognosis.
    Sun D; Zhu Y; Zhao H; Bian T; Li T; Liu K; Feng L; Li H; Hou H
    Cell Oncol (Dordr); 2021 Oct; 44(5):1019-1034. PubMed ID: 34109546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ADAM12 promotes the resistance of lung adenocarcinoma cells to EGFR-TKI and regulates the immune microenvironment by activating PI3K/Akt/mTOR and RAS signaling pathways.
    Li K; Quan L; Huang F; Li Y; Shen Z
    Int Immunopharmacol; 2023 Sep; 122():110580. PubMed ID: 37418984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer.
    Liu C; Zheng S; Wang Z; Wang S; Wang X; Yang L; Xu H; Cao Z; Feng X; Xue Q; Wang Y; Sun N; He J
    Cancer Commun (Lond); 2022 Sep; 42(9):828-847. PubMed ID: 35811500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ARID1A serves as a receivable biomarker for the resistance to EGFR-TKIs in non-small cell lung cancer.
    Sun D; Teng F; Xing P; Li J
    Mol Med; 2021 Oct; 27(1):138. PubMed ID: 34715776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive value of CD73 expression for the efficacy of immune checkpoint inhibitors in NSCLC.
    Ishii H; Azuma K; Kawahara A; Kinoshita T; Matsuo N; Naito Y; Tokito T; Yamada K; Akiba J; Hoshino T
    Thorac Cancer; 2020 Apr; 11(4):950-955. PubMed ID: 32061060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical characteristics of patients treated with immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: CS-Lung-003 prospective observational registry study.
    Kuribayashi T; Ohashi K; Nishii K; Ninomiya K; Tsubata Y; Ishikawa N; Kodani M; Kanaji N; Yamasaki M; Fujitaka K; Kuyama S; Takigawa N; Fujimoto N; Kubota T; Inoue M; Fujiwara K; Harita S; Takata I; Takada K; Okawa S; Kiura K; Hotta K
    J Cancer Res Clin Oncol; 2024 Feb; 150(2):89. PubMed ID: 38347279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Junctional adhesion molecule-like protein as a novel target for kaempferol to ameliorate lung adenocarcinoma.
    Wu Q; Wang YB; Che XW; Wang H; Wang W
    J Integr Med; 2023 May; 21(3):268-276. PubMed ID: 37069006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LPCAT1 promotes brain metastasis of lung adenocarcinoma by up-regulating PI3K/AKT/MYC pathway.
    Wei C; Dong X; Lu H; Tong F; Chen L; Zhang R; Dong J; Hu Y; Wu G; Dong X
    J Exp Clin Cancer Res; 2019 Feb; 38(1):95. PubMed ID: 30791942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. APE1 stimulates EGFR-TKI resistance by activating Akt signaling through a redox-dependent mechanism in lung adenocarcinoma.
    Lu GS; Li M; Xu CX; Wang D
    Cell Death Dis; 2018 Oct; 9(11):1111. PubMed ID: 30382076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Knockdown of replication protein A 3 induces protective autophagy and enhances cisplatin sensitivity in lung adenocarcinoma by inhibiting AKT/mTOR signaling via binding to cyclin-dependent kinases regulatory subunit 2.
    Chen L; Hu K; Liu Y; Liu L; Tang J; Qin X
    Drug Dev Res; 2022 Nov; 83(7):1589-1599. PubMed ID: 35903032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC).
    Hsu PC; Jablons DM; Yang CT; You L
    Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31387256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy.
    Chen K; Cheng G; Zhang F; Zhu G; Xu Y; Yu X; Huang Z; Fan Y
    Lung Cancer; 2020 Apr; 142():98-105. PubMed ID: 32120230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidermal Growth Factor Receptor Mutations in Resectable Non-Small Cell Lung Cancer Patients and their Potential Role in the Immune Landscape.
    Xia W; Mao W; Chen R; Lu R; Liu F; He Y; Wang S; Li X; Zheng M
    Med Sci Monit; 2019 Nov; 25():8764-8776. PubMed ID: 31746315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.